CLSN
Celsion Announces Impressive Preclinical Data for its GEN-1 IL-12 Immunotherapy in Combination with Avastin(R) and Doxil(R) for Ovarian Cancer
Results from the comprehensive studies confirmed remarkable initial GEN-1 + Avastin findings and show convincingly that GEN-1 when combined with Avastin® and Doxil®, standard of care for platinum resistant patients, demonstrated a greater than 98% reduction in tumor burden when compared to the untreated control group.
Analysis of serum chemistry and hematology suggested no overt toxicities associated with the combined treatments
The Company is currently enrolling patients in the OVATION Study, a Phase 1b dose escalating trial combining GEN-1 with neo-adjuvant therapies in newly diagnosed ovarian cancer patients which will provide a starting dose for the follow-on Phase 1/2 study combining GEN-1 with Avastin® and Doxil®. The Phase 1/2 combination trial is expected to begin in mid-2016. We look forward to completing enrollment of the OVATION Study, next year, followed by the launch of this combination trial later in 2016."
Reduction in Mean Tumor Burden vs. Untreated Control
GEN-1 Immunotherapy 84%
Avastin® + LD Doxil® 77%
Avastin® + HD Doxil® 88%
Avastin® + LD Doxil® + GEN-1 > 98%
Avastin® + HD Doxil® + GEN-1 > 98%
http://investor.celsion.com/releaseDetail.cfm?ReleaseID=936132
PS: con los últimos datos que está arrojando, diría que la empresa puede volver a despertar interés a los precios actuales, pero habría que mirar antes cómo van de cash, que hace tiempo que no lo sigo.
«Después de nada, o después de todo/ supe que todo no era más que nada.»